http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yo-Seok Cho,Hyuk-Joon Lee,Shin-Hoo Park,Tae-Han Kim,Hwi Nyeong Choe,Yun-Suhk Suh,Seong-Ho Kong,Han-Kwang Yang 대한종양외과학회 2017 Korean Journal of Clinical Oncology Vol.13 No.2
Purpose: This study evaluated the adequacies of lymph node (LN) dissection according to the second version (determined by tumor location) or third/fourth version (determined by surgery extent) of the Japanese gastric cancer treatment guidelines. Methods: Prospectively collected data of 3,948 gastric cancer patients who underwent gastrectomy were analyzed. The prevalence of LN metastasis and 5-year survival were analyzed according to tumor invasion depth and tumor location. In early gastric cancer (EGC), the frequency of LNs were evaluated. In advanced gastric cancer (AGC), the frequency of LN metastasis and the 5-year survival rate of patients with positive LN were evaluated. Results: For lower-third EGC, the positive rates for the #1 and #4sb were 0.93% and 0%. For upper-third EGC, the positive rates for #4d, #5, #6, and #11p were 0.3%, 0%, 0.76%, and 1.22%. For lower-third AGC, the positive rates for #4sb and #14v were 2.48% and 7.64%, and the 5-year survival rates were 69.2% and 12.5%, respectively. For upper-third AGC, the positive rates for #5, #6, and #12a were 2.33%, 2.57%, and 2.03%, and the 5-year survival rates were 21.8%, 64.3%, and 0%, respectively. Conclusion: According to our analysis, in EGC, LN dissection in second edition seems more suitable, however LN dissection in #11p would be mandatory in upper third EGC. In AGC, LN dissection in third/fourth edition seems more suitable in terms of frequency of LN metastasis and survival rate.
UPS용 인버터의 LC필터 출력 전압제어를 위한 디지털 제어기 설계
조준석(Jun-Seok Cho),이승요(Seung-Yo Lee),최규하(Gyu-Ha Choe),목형수(Hyung-Soo Mok),신우석(Woo-Seok Shin),한석우(Seok-Woo Han) 전력전자학회 1998 전력전자학술대회 논문집 Vol.- No.-
This paper presents an observer filter algorithm to estimate the load currents in the output voltage control of 3-phase uninterruptible power supply with deadbeat controller As the result of the proposed algorithm, the sensors to measure the<br/> load currents is not required The comparison of output voltage controls according to the methods of measuring the load currents is also presented in this paper The results of comparison are shown by the simulation.<br/> <br/>
Cho, Yang-Je,Heo, Kyoung,Kim, Won-Joo,Jang, Sang Hyun,Jung, Yo Han,Ye, Byoung Seok,Song, Dong Beom,In Lee, Byung Blackwell Publishing Ltd 2009 Epilepsia Vol.50 No.8
<P>Summary</P><P><U>Purpose:</U> </P><P>To evaluate the long-term efficacy and tolerability of topiramate (TPM) as add-on therapy in patients with refractory partial epilepsy.</P><P><U>Methods:</U> </P><P>This is a retrospective, single-center, long-term observational study. Patients fulfilling the criteria of medical intractability proposed by Berg et al. were entered into the study if they were newly prescribed TPM as add-on therapy between January 2000 and June 2002. The usual starting dosage of TPM was 50 mg/day and optimal-dose adjustments were made according to individual clinical responses. Efficacy and tolerability were analyzed every year during 5-year follow-up in the “intention-to-treat (ITT) population.” Retention rate was estimated by Kaplan-Meyer analysis.</P><P><U>Results:</U> </P><P>A total of 125 patients were included in the study and 107 patients (85.6%) were followed for 5 years. Retention rate was 87.2% at 1 year and 64% at 5 years. At the end of 5 years, the median seizure frequency reduction rate was 69.0% and responder rate was 43.2% in the ITT population. Cumulative seizure-free rate (SFR) was 30.4% and the terminal 1-year SFR was 12.8% in the ITT population (20.0% in completers) at 5-year follow-up. Adverse events (AEs) occurred in 39.2% of patients, including significant AEs leading to antiepileptic drug (AED) withdrawal in 14.4%. The most common AEs were anorexia (16.0%), weight loss (10.4%), and gastrointestinal symptoms (8.8%). Concomitant AEDs were reduced in 25.0% of the completers.</P><P><U>Discussion:</U> </P><P>Low-dose and slow-dose escalation of TPM in add-on therapy for patients with refractory partial epilepsy is effective and well tolerated in long-term, individualized clinical practice.</P>
Cho, Sung-Hwan,Park, Shin Young,Lee, Eun Jeong,Cho, Yo Han,Park, Hyun Sun,Hong, Seok-Ho,Kim, Woo Jin The Korean Academy of Tuberculosis and Respiratory 2015 Tuberculosis and Respiratory Diseases Vol.78 No.2
Background: Aryl hydrocarbon receptor (AhR), a ligand-dependent transcription factor, binds to a wide variety of synthetic and naturally occurring compounds. AhR is involved in the regulation of inflammatory response during acute and chronic respiratory diseases. We investigated whether nuclear receptor coactivator 7 (NCOA7) could regulate transcriptional levels of AhR target genes and inflammatory cytokines in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated human bronchial epithelial cells. This study was based on our previous study that NCOA7 was differentially expressed between normal and chronic obstructive pulmonary disease lung tissues. Methods: BEAS-2B and A549 cells grown under serum-free conditions were treated with or without TCDD (0.15 nM and 6.5 nM) for 24 hours after transfection of pCMV-NCOA7 isoform 4. Expression levels of cytochrome P4501A1 (CYP1A1), IL-6, and IL-8 were measured by quantitative real-time polymerase chain reaction. Results: The transcriptional activities of CYP1A1 and inflammatory cytokines were strongly induced by TCDD treatment in both BEAS-2B and A549 cell lines. The NCOA7 isoform 4 oppositely regulated the transcriptional activities of CYP1A1 and inflammatory cytokines between BEAS-2B and A549 cell lines. Conclusion: Our results suggest that NCOA7 could act as a regulator in the TCDD-AhR signaling pathway with dual roles in normal and abnormal physiological conditions.
Cho, Hee Jun,Kim, Jong-Tae,Lee, Seon-Jin,Hwang, Yo Sep,Park, Sang Yoon,Kim, Bo-Yeon,Yoo, Jiyun,Hong, Kwan Soo,Min, Jeong-Ki,Lee, Chul-Ho,Lim, Jong-Seok,Yoon, Suk Ran,Choi, Inpyo,Choe, Yong-Kyung,Lee, Elsevier 2018 Cancer letters Vol.417 No.-
<P><B>Abstract</B></P> <P>Rho GTPases control a wide range of cellular processes, and their deregulation is associated with promotion of an aggressive and metastatic tumor phenotype in human cancers. Rho guanine nucleotide dissociation inhibitor 1 (RhoGDI1) plays a key role in regulating the activity of Rho GTPases. However, the underlying mechanisms are still unclear. In this study, we show that protein phosphatase 1B (PPM1B) interacts with RhoGDI1 and functions as its phosphatase. Ectopic expression of PPM1B results in dephosphorylation of RhoGDI1 and, thereby, abates the activation of RhoA, Rac1 and CDC42 by epidermal growth factor (EGF). PPM1B overexpression in Hs578T and SKBR3 human breast cancer cells decreases their motility and invasiveness <I>in vitro</I> and cancer metastasis <I>in vivo</I>. In contrast, knockdown of PPM1B in MCF-7 and MDA-MB-468 human breast cancer cells that express endogenous PPM1B enhances EGF-induced RhoGDI1 phosphorylation, activation of Rho GTPases, and cancer cell migration and invasion. Knockdown of RhoA or Rac1 by siRNA reverses the enhanced cell migration seen after PP1MB depletion. Collectively, these results indicate that PPM1B negatively regulates cancer cell motility and invasiveness through dephosphorylating RhoGDI1.</P> <P><B>Highlights</B></P> <P> <UL> <LI> PPM1B interacts with RhoGDI1 and functions as its phosphatase. </LI> <LI> PPM1B abates the activation of RhoA, Rac1, and Cdc42 by EGF. </LI> <LI> PPM1B suppresses the migration and invasion of cancer cells <I>in vitro</I> and tumor metastasis <I>in vivo.</I> </LI> <LI> We provides new insight into the molecular mechanism by which PPM1B regulates the migration and invasion of cancer cells. </LI> </UL> </P>